SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sloka, J S
Right arrow Articles by Stefanelli, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sloka, J S
Right arrow Articles by Stefanelli, M
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The mechanism of action of methylprednisolone in the treatment of multiple sclerosis

J S Sloka

Faculty of Medicine (Neurology), Memorial University of Newfoundland, NL, Canada, p97jss{at}mun.ca

M Stefanelli

Health Sciences Centre, St. John’s, NL, Canada

Methylprednisolone plays an important role in the current treatment of multiple sclerosis (MS), particularly in the acute phase of relapse. It acts in various ways to decrease the inflammatory cycle including: dampening the inflammatory cytokine cascade, inhibiting the activation of T cells, decreasing the extravasation of immune cells into the central nervous system, facilitating the apoptosis of activated immune cells, and indirectly decreasing the cytotoxic effects of nitric oxide and tumor necrosis factor alpha. This paper reviews the most recent observations on these mechanisms both to understand the disease mechanism and its treatment. As more becomes known about these mechanisms, it may become possible to design treatment regimes that are more specific towards both the individual and the disease state.

Key Words: mechanism • methylprednisolone • multiple sclerosis

Multiple Sclerosis, Vol. 11, No. 4, 425-432 (2005)
DOI: 10.1191/1352458505ms1190oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
V. Martinelli, M. A. Rocca, P. Annovazzi, A. Pulizzi, M. Rodegher, F. M. Boneschi, R. Scotti, A. Falini, M. P. Sormani, G. Comi, et al.
A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS
Neurology, December 1, 2009; 73(22): 1842 - 1848.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
M Matysiak, B Makosa, A Walczak, and K Selmaj
Patients with multiple sclerosis resisted to glucocorticoid therapy: abnormal expression of heat-shock protein 90 in glucocorticoid receptor complex
Multiple Sclerosis, August 1, 2008; 14(7): 919 - 926.
[Abstract] [PDF]

Home page
 Mult SclerHome page
S. Kern and T. Ziemssen
Review: Brain immune communication psychoneuroimmunology of multiple sclerosis
Multiple Sclerosis, January 1, 2008; 14(1): 6 - 21.
[Abstract] [PDF]

Home page
 NEJMHome page
R. M. Ransohoff
Natalizumab for Multiple Sclerosis
N. Engl. J. Med., June 21, 2007; 356(25): 2622 - 2629.
[Full Text] [PDF]


Advertisement